Advantage Investment Management’s Jounce Therapeutics, Inc. Common Stock JNCE Stock Holding History

Advantage Investment Management’s Portfolio JNCE Stock Details JNCE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	$2K	Hold	600	–	–	﹤0.01%	871
2019 Q2	$3K	Hold	600	–	–	﹤0.01%	845
2019 Q1	$4K	Hold	600	–	–	﹤0.01%	810
2018 Q4	$2K	Hold	600	–	–	﹤0.01%	927
2018 Q3	$4K	Hold	600	–	–	﹤0.01%	885
2018 Q2	$5K	Hold	600	–	–	﹤0.01%	778
2018 Q1	$13K	Buy	+600	New	+$13.3K	0.01%	632

Other funds holding JNCE

TGI

TRV GP II Boston, Massachusetts $1.34M AUM 67.55% 1-Year Est. Return

TGI

TRV GP III Boston, Massachusetts $6.14M AUM 45.44% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

EAM

Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return

OFM

Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Advantage Investment Management's JNCE Position: Q3 2019 in Review

Advantage Investment Management held its Jounce Therapeutics, Inc. Common Stock (JNCE) position steady in Q3 2019 at 600 shares worth $2K. The position accounts for ﹤0.01% of the portfolio, ranked #871.

Advantage Investment Management first reported a position in JNCE in Q1 2018 and has held it in 7 quarters since. The position peaked at $13K in Q1 2018. 77 funds tracked by Wall St. Rank hold JNCE as of Q3 2019.

Advantage Investment Management held 600 shares of Jounce Therapeutics, Inc. Common Stock worth $2K as of Q3 2019.
Advantage Investment Management left its Jounce Therapeutics, Inc. Common Stock share count unchanged in Q3 2019.
Jounce Therapeutics, Inc. Common Stock made up ﹤0.01% of Advantage Investment Management's portfolio in Q3 2019, its #871 holding.
Advantage Investment Management first reported a position in Jounce Therapeutics, Inc. Common Stock in Q1 2018 and has held it in 7 quarters since.
Advantage Investment Management's Jounce Therapeutics, Inc. Common Stock position peaked at $13K in Q1 2018.
77 funds tracked by Wall St. Rank held Jounce Therapeutics, Inc. Common Stock as of Q3 2019.

Based on Advantage Investment Management's 13F filing for Q3 2019, filed 8 Oct 2019.